6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. (Q47791116)
Jump to navigation
Jump to search
scientific article published on 13 May 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. |
scientific article published on 13 May 2009 |
Statements
1 reference
6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. (English)
1 reference
1 reference
1 reference
Alexios-Leandros Skaltsounis
1 reference
Laurent Meijer
1 reference
Evangelia Xingi
1 reference
Despina Smirlis
1 reference
Ketty Soteriadou
1 reference
13 May 2009
1 reference
39
1 reference
12
1 reference
1289-1303
1 reference
Identifiers
1 reference
1 reference